Overview
A comprehensive overview of the role of IL-17/Th17 in inflammatory disorders and discussion of the latest therapeutic advances targeting this pathway
Includes the latest evidence-based treatment recommendations based on the most up-to-date research and clinical trial data
A wide range of engaging images, tables, and diagrams illustrate the concepts discussed in the book
Written by a renowned international expert on IL-17 research in the clinical setting
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (6 chapters)
-
Front Matter
Keywords
About this book
This book provides an overview of the discovery and structure of IL-17, including its pathogenesis and role in chronic inflammation and autoimmunity. To capture the latest developments and product approvals the book also discusses the therapeutic advances and looks at emerging therapies targeting the IL-17 pathway. IL-17 is a pro-inflammatory cytokine that has a key role in inflammation, autoimmunity, and host defense in a number of inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis and psoriasis, ankylosing spondylitis, multiple sclerosis, and inflammatory bowel disease. The discovery of the IL-17-Th17 pathway has seen exciting development in the field of immunology and inflammation research, which has led to a number of recent regulatory approvals.
Authors and Affiliations
About the author
Cong-Qiu Chu, MD, PhD is associate professor of medicine at Oregon Health & Science University and VA Portland Health Care System, Portland, Oregon. Dr Chu obtained his MD from Normal Bethune University of Medical Sciences, Changchun, China and PhD from the Kennedy Institute of Rheumatology, University of London, London, UK; completed his internal medicine residency at Peking Union Medical College Hospital, Beijing and Wayne State University Detroit Medical Center, Detroit, Michigan and rheumatology fellowship at University of Washington, Seattle. Dr Chu has a career long interest in the pathogenesis of rheumatoid arthritis (RA). His seminal observation that tumor necrosis factor (TNF) is over-expressed in RA joint tissue helped the development of TNF inhibitors for therapy of RA. His contribution was recognized by European League Against Rheumatism Young Investigator Award in 1991. Dr Chu is one of the investigators who first demonstrated that T helper type 1 (Th1) cells are not the cell types mediating autoimmune inflammatory diseases, which were later uncovered to be mediated by Th17 cells. Dr Chu’s current research includes developing novel therapeutic strategies using RNA interference technology for precise targeting Th17 cells for inflammatory diseases and developing optimal management strategies for early RA.
Bibliographic Information
Book Title: Targeting the IL-17 Pathway in Inflammatory Disorders
Authors: Cong-Qiu Chu
DOI: https://doi.org/10.1007/978-3-319-28040-0
Publisher: Adis Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer International Publishing Switzerland 2017
License: CC BY
Softcover ISBN: 978-3-319-28039-4Published: 28 December 2016
eBook ISBN: 978-3-319-28040-0Published: 26 November 2016
Edition Number: 1
Number of Pages: XV, 102
Number of Illustrations: 6 illustrations in colour
Topics: Rheumatology, Dermatology, Pharmacotherapy, Primary Care Medicine, Public Health